As Chief Technology Officer at Exothera, Belgium, Hanna’s primary responsibilities are technology development and innovation in bioproduction platforms. Hanna has made her whole career in the gene therapy field. Over the years she has been in several directors positions leading research and development at FKD Therapies, Finvector, and Kuopio Center for Gene and Cell Therapy. Her research interest has focused on gene therapy and translational development, including early-stage analytics and the development of scalable, robust manufacturing processes operating under current regulatory guidelines. Her PhD was in Molecular Medicine, obtained from the University of Kuopio. She followed up her PhD with post-doc work at the University of California San Diego UCSD, CA, the USA, and the University of Eastern Finland, Kuopio, Finland. She has several patents related to vector manufacturing.